Nancy Shulman M.D.

Nancy Shulman, MD has extensive work experience in the pharmaceutical and biotechnology industry, as well as in academia. Nancy is currently the Chief Medical Officer at BlueJay Therapeutics since 2022. Prior to that, they worked as the VP of Translational Medicine at Ambys Medicines from 2019 to 2022.

From 2013 to 2019, Dr. Shulman held various leadership roles at AbbVie. These roles included Group Medical Director for Oncology Early Development, Sr. Medical Director for Oncology Research and Development, Executive Medical Director for Infectious Diseases/Hepatology Research and Development, and Group/Senior Medical Director for Virology Research and Development.

Before joining AbbVie, Dr. Shulman worked at Genentech from 2011 to 2013 as a Biomarker/Personalized Health Care Leader in Immunology and Infectious Disease Development, and as a Clinical Science Leader/Medical Director in Virology.

Prior to their industry roles, Dr. Shulman held the position of Virology Translational Medicine Leader at Roche from 2008 to 2011.

Dr. Shulman began their career in academia, working at Stanford University School of Medicine from 2000 to 2008 as an Instructor/Assistant Professor in Medicine, specializing in Infectious Diseases.

Dr. Nancy Shulman completed their education in a chronological order as follows:

From 1983 to 1987, they attended The University of Texas at Austin, where they earned a Bachelor of Arts in Biochemistry with a minor in Mandarin Chinese.

Nancy then pursued a medical degree from 1987 to 1991 at the University of Kansas Medical Center.

Following this, Dr. Shulman completed their residency in Internal Medicine and Pediatrics from 1991 to 1995 at The University of Chicago Pritzker School of Medicine.

Finally, from 1996 to 2000, they attended Stanford University School of Medicine, where they completed a Postdoctoral Fellowship in Infectious Diseases.